Haleon, a GSK spinoff, anticipates a 4-6% sales increase in 2023.
Reuters reports from London. Haleon, the world’s largest standalone consumer health company, forecasted a 4-6% increase in organic sales in 2023 on Thursday.
Last year, the London-listed firm, which includes health assets previously held by GSK and Pfizer (NYSE:PFE), posted an organic sales increase of 9%.
The producer of Sensodyne toothpaste and Panadol pain relievers predicted an 8–8.5% rise in sales last year in November.